Month: July 2024

CLICK HERE to see the results video

We highlight in this half of 2024:

In this half-year, special attention should be drawn to the 2.8 percentage point increase in the gross margin when compared with the first half of 2023, rising to 59.4%.

Operating revenue decreased 14%, mainly due to a lower contribution from the CDMO business, sales of which decreased to 118.9 million euros.

Operating revenue generated by the specialty pharmaceutical business increased 1% to 210.5 million euros.

Sales of the heparin division (low-molecular-weight heparins and other heparins) totalled 120.7 million euros in the first half of the year.

Low-molecular-weight heparins decreased 2% to 116.9 million euros in the first half of 2024, mainly due to the drop in enoxaparin sales. However, a greater concentration of orders from partners is expected in the second half of 2024.

Bemiparin sales increased 6%, driven mainly by a higher volume of orders from partners in China, Turkey and Greece.

ROVI expects bemiparin sales to increase by a low-single-digit percentage in 2024 compared with 2023. Risperidone ISM® sales rose 141% in the first half of 2024 versus the same period of 2023, totalling 12.5 million euros.

In 2024, this product has been approved in the United States, Canada and Australia, thus reinforcing ROVI’s internationalisation strategy. Risperidone ISM® is expected to reach potential sales of between 200 and 300 million euros globally in upcoming years. R&D expenses rose 13% to 12.2 million euros. Regarding guidance for 2024, ROVI expects its operating revenue to decrease by a mid-single-digit percentage, although this guidance considers certain factors that could affect the estimates but are difficult to specify at present.

Here you can review the new Training Policy of the ROVI Group, in which are described the processes for identifying needs and planning training activities for the ROVI’s workforce.

You can find it on ROVI’s website and in the Documents section of ROVI Rocks.

We’ll be waiting for you

Get ready for the change

The Investment Accelerator of the Community of Madrid has declared as a strategic project the expansion that Laboratorios ROVI will undertake at its plant in San Sebastián de los Reyes (Madrid), with which it plans to increase its current production capacity, thanks to the commissioning of a new high-speed line with a capacity of 100 million syringes.

The expansion project will involve an investment of around 60 million euros. The group has acquired adjoining land for a total area of 54,715 m2, which will increase production capacity by more than 31.5 percent to a total of 420 million prefilled syringes and 80 million vials by 2027.

To respond to the increase in activity, the group will incorporate new buildings for the expansion of production areas and new lines, a new quality laboratory and office building, and auxiliary storage and maintenance buildings, among others. The project envisages providing the industrial complex with new accesses and improving internal circulation, as well as increasing the number of parking spaces to meet the needs of the current and future workforce.

The various investments to increase the plant’s production capacity between 2023 and 2027 will create 200 new direct skilled jobs.

With this, the ROVI Group is positioned as one of the largest industrial pharmaceutical groups in Spain and among the world leaders in the production of injectables.

We are pleased to inform you that you have at your disposal the new version of the ROVI Group’s Environmental and Social Sustainability Policy, approved on 24 June 2024.

This document sets out the basic principles of the company’s sustainable behaviour in relation to its stakeholders.

As well as attached in this e-mail, you will find the policy on ROVI’s web site.